Antithrombotic Therapy

 

The Practical Cardiology™ Antithrombotic Therapy clinical resource center offers updates and information about the latest in the fields of antiplatelet and anticoagulation therapy. On this page you will find content related to FDA approvals and the latest information for preventing thrombosis in the form of articles, video interviews with leading experts, clinician-authored columns, and more.

FDA Approves Rivaroxaban for 2 New Pediatric Indications

December 21, 2021

Announced on Dec. 20, the latest approvals for rivaroxaban (Xarelto) mark the 10th and 11th indications for the factor Xa inhibitor in the US.

Cardiology Month in Review: November 2021

November 27, 2021

November's cardiology month in review features stories from the AHA's late-breaking sessions and Kidney Week 2021.

AHA 2021: Top Data Slideshow

November 17, 2021

Every year, AHA Scientific Sessions provides clinicians and researchers with a glimpse into the latest data from clinical trials. Our editorial staff's top picks for late-breaking data from AHA 2021 Scientific Sessions includes AVATAR, RAPID CABG, REVERSE-IT, and more.

REVERSE-IT: Bentracimab Shows Promise as Fast-Acting Ticagrelor Reversal Agent

November 15, 2021

Deepak Bhatt, MD, MPH, discusses the results of the interim analysis of the REVERSE-IT trial presented at AHA 2021, which indicates bentracimab provided immediate and sustained reversal of ticagrelor's antiplatelet effects in patients requiring urgent surgery or experiencing major bleeding.

Dabigatran and Warfarin Provide Similar Effect on Cognitive Function in AFib

November 15, 2021

After 2 years, there was little difference in cognitive function between patients with nonvalvular atrial fibrillation receiving dabigatran or warfarin in the GIRAF trial, which was presented at AHA 2021.

ESC Congress 2021: Top Trials Slideshow

August 31, 2021

Every year, ESC Congress provides clinicians and researchers with a glimpse into the latest data from clinical trials. Our editorial staff's top picks for new trials from ESC Congress 2021 conference includes EMPEROR-Preserved, FIGARO-DKD, SSaSS, MASTER DAPT, and the LOOP Study.

ENVISAGE-TAVI AF: Clinical Implications and Next Steps, With George Dangas, MD, PhD

August 31, 2021

George Dangas, MD, PhD, discusses the results of ENVISAGE-TAVI AF and provides perspective into the priorities of investigators as they plan and conduct additional analyses of the trial.

TWILIGHT-Stent: Results Consistent Regardless of Stent Type

August 31, 2021

Results of the TWILIGHT-Stent study provide insight into the impact of stent type on effects of ticagrelor monotherapy compared against ticagrelor plus aspirin among patients within the original TWILIGHT trial.

Ticagrelor Monotherapy Reduces Bleeding Events vs DAPT with Aspirin in HBR Patients

August 30, 2021

TWILIGHT-HBR suggests ticagrelor monotherapy could lower bleeding risk among patients meeting ARC-HBR criteria. Study presenter Davide Cao, MD, offers further perspective on results of the post hoc analysis.

TWILIGHT Analysis Suggests Ticagrelor Monotherapy Preferable in Concomitant Diabetes and CKD

August 30, 2021

A post hoc analysis of the TWILIGHT trial suggests the effects of ticagrelor monotherapy observed in the overall trial were consistent, irrespective of diabetes and chronic kidney disease status.